JP2008503517A - 抗血管形成作用を有する医薬の製造のためのトリフルオロ酢酸カルシウムの使用 - Google Patents
抗血管形成作用を有する医薬の製造のためのトリフルオロ酢酸カルシウムの使用 Download PDFInfo
- Publication number
- JP2008503517A JP2008503517A JP2007517152A JP2007517152A JP2008503517A JP 2008503517 A JP2008503517 A JP 2008503517A JP 2007517152 A JP2007517152 A JP 2007517152A JP 2007517152 A JP2007517152 A JP 2007517152A JP 2008503517 A JP2008503517 A JP 2008503517A
- Authority
- JP
- Japan
- Prior art keywords
- angiogenesis
- manufacture
- medicament
- calcium trifluoroacetate
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
【選択図】なし
Description
大人では、内皮細胞は非常に遅い代謝回転を示し、血管形成は、例えば、創傷回復及び女性の生殖系(排卵、月経、移植及び妊娠)の周期的プロセス等の生理的条件に制限される。組織代謝の要求に関する限り、生理的血管形成は厳しくコントロールされ、短い期間活性化され、次いで、すぐに阻害される。
欧州特許第1423131号は、トリフルオロ酢酸カルシウムが及びその関連カルシウム塩は、動物の実験的なモデルにおいて腫瘍成長を阻害し、インビトロにおいて、固形腫瘍細胞に対して細胞毒性活性を示す。
著しい血管形成が、予想通り、VEGF(40ng/ml)を含むマトリゲルプラグで、予想通り観察された。VEGFの作用は、トリフルオロ酢酸カルシウムで処置されたマウスで激減した。この強い抗血管形成作用は、早くも肉眼的に観察することができ、組織学的に確認することができた。形態測定分析は、トリフルオロ酢酸カルシウム2μg/マウスの用量で40%以上、4μg/マウスの用量で80%以上の血管形成の減少を示した。
これらのデータは、トリフルオロ酢酸カルシウムが成長因子による刺激に対する内皮細胞の反応を阻害することができることを示唆し、カルシウムチャネルを通してメッセージ伝達に作用するようである。
従って、トリフルオロ酢酸カルシウムは、血管形成の阻害が必要であるか、適切である病態の治療のために、適当な医薬組成物の形態で、良好に使うことができる。その病態の例は、上記のように、アテローム動脈硬化性プラーク、慢性関節リウマチ、乾癬、糖尿病性網膜症、酒さ、ケロイド及び血管新生のための他病気又は皮膚無感覚症(inaesthetisms)を含む。さらに、トリフルオロ酢酸カルシウムは、固形腫瘍の発症を防止する抗転移(antimetastatic)剤として有効であるかもしれない。
トリフルオロ酢酸カルシウムは、補完的であるか、いずれにしろ有効な活性を有する他の活性成分と、任意に組み合わせられるであろう。
Claims (3)
- 抗血管形成作用を有する医薬の製造のためのトリフルオロ酢酸カルシウムの使用。
- アテローム動脈硬化性プラーク、慢性関節リウマチ、乾癬、糖尿病性網膜症、酒さ、ケロイドの治療用医薬の製造のための請求項1の使用。
- 血管形成によって媒介される腫瘍成長に活性を有する医薬の製造のための請求項1の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001279A ITMI20041279A1 (it) | 2004-06-24 | 2004-06-24 | Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico |
ITMI2004A001279 | 2004-06-24 | ||
PCT/EP2005/006533 WO2006000339A2 (en) | 2004-06-24 | 2005-06-17 | Calcium trifluoroacetate for preparing antiangiogenetic medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008503517A true JP2008503517A (ja) | 2008-02-07 |
JP4903694B2 JP4903694B2 (ja) | 2012-03-28 |
Family
ID=35134535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007517152A Expired - Fee Related JP4903694B2 (ja) | 2004-06-24 | 2005-06-17 | 抗血管形成作用を有する医薬の製造のためのトリフルオロ酢酸カルシウムの使用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070260088A1 (ja) |
EP (1) | EP1763343B1 (ja) |
JP (1) | JP4903694B2 (ja) |
AT (1) | ATE453388T1 (ja) |
DE (1) | DE602005018642D1 (ja) |
DK (1) | DK1763343T3 (ja) |
ES (1) | ES2339263T3 (ja) |
IT (1) | ITMI20041279A1 (ja) |
PL (1) | PL1763343T3 (ja) |
PT (1) | PT1763343E (ja) |
SI (1) | SI1763343T1 (ja) |
WO (1) | WO2006000339A2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007058360B3 (de) * | 2007-12-03 | 2009-04-30 | Heraeus Quarzglas Gmbh & Co. Kg | Verfahren zur Herstellung einer erhabenen Markierung auf einem Glasgegenstand |
EP2796135A1 (en) * | 2013-04-22 | 2014-10-29 | Polichem S.A. | Use of trifluoroacetic acid and salts thereof to treat hypercholesterolemia |
EP2845591A1 (en) | 2013-09-04 | 2015-03-11 | Polichem S.A. | Use of trifluoroacetic acid as keratolytic agent to treat hyperkeratotic skin lesions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003006031A1 (en) * | 2001-07-12 | 2003-01-23 | Bilton - Consultadoria E Marketing Lda. | Calcium salts with cytotoxic activity |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880660A (en) * | 1987-08-28 | 1989-11-14 | Minnesota Mining And Manufacturing Company | Method for priming hard tissue |
IT1236512B (it) * | 1989-10-06 | 1993-03-11 | Eniricerche Spa | Elettrolita polimerico solido a base poliepossidica. |
CN1058390C (zh) * | 1993-10-15 | 2000-11-15 | 伊莱利利公司 | 苯并噻吩类化合物的用途 |
US5593987A (en) * | 1993-12-21 | 1997-01-14 | Eli Lilly And Company | Methods of inhibiting breast disorders |
US6380366B1 (en) * | 1994-04-28 | 2002-04-30 | Les Laboratoires Aeterna Inc. | Shark cartilage extract:process of making, methods of using and compositions thereof |
US6083990A (en) * | 1997-04-02 | 2000-07-04 | Pharmos Corporation | Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones |
US6703050B1 (en) * | 1998-09-04 | 2004-03-09 | The Regents Of The University Of Michigan | Methods and compositions for the prevention or treatment of cancer |
IT1317001B1 (it) * | 2000-03-13 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Uso della spirolaxina per il trattamento di patologie associate ad unaalterata angiogenesi. |
US20040053943A1 (en) * | 2000-11-20 | 2004-03-18 | Adams Jerry L. | Novel compounds |
ITMI20040665A1 (it) * | 2004-04-02 | 2004-07-02 | Pharmaproducts Uk Ltd | Sale di calcio per il trattamento della psoriasi e di dermatiti |
-
2004
- 2004-06-24 IT IT001279A patent/ITMI20041279A1/it unknown
-
2005
- 2005-06-17 DK DK05758830.3T patent/DK1763343T3/da active
- 2005-06-17 EP EP05758830A patent/EP1763343B1/en not_active Not-in-force
- 2005-06-17 AT AT05758830T patent/ATE453388T1/de active
- 2005-06-17 PL PL05758830T patent/PL1763343T3/pl unknown
- 2005-06-17 PT PT05758830T patent/PT1763343E/pt unknown
- 2005-06-17 DE DE602005018642T patent/DE602005018642D1/de active Active
- 2005-06-17 SI SI200530944T patent/SI1763343T1/sl unknown
- 2005-06-17 ES ES05758830T patent/ES2339263T3/es active Active
- 2005-06-17 WO PCT/EP2005/006533 patent/WO2006000339A2/en active Application Filing
- 2005-06-17 JP JP2007517152A patent/JP4903694B2/ja not_active Expired - Fee Related
- 2005-06-17 US US11/630,434 patent/US20070260088A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003006031A1 (en) * | 2001-07-12 | 2003-01-23 | Bilton - Consultadoria E Marketing Lda. | Calcium salts with cytotoxic activity |
Also Published As
Publication number | Publication date |
---|---|
WO2006000339A2 (en) | 2006-01-05 |
DE602005018642D1 (de) | 2010-02-11 |
JP4903694B2 (ja) | 2012-03-28 |
PL1763343T3 (pl) | 2010-07-30 |
EP1763343A2 (en) | 2007-03-21 |
US20070260088A1 (en) | 2007-11-08 |
WO2006000339A3 (en) | 2006-08-03 |
ES2339263T3 (es) | 2010-05-18 |
PT1763343E (pt) | 2010-03-24 |
SI1763343T1 (sl) | 2010-05-31 |
DK1763343T3 (da) | 2010-05-03 |
ITMI20041279A1 (it) | 2004-09-24 |
EP1763343B1 (en) | 2009-12-30 |
ATE453388T1 (de) | 2010-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU784496B2 (en) | Use of chemotherapeutic agents | |
JP2007532663A (ja) | ニューロパシー性の糖尿病性足潰瘍を治療するためのトレプロスチニルの使用 | |
WO2002022128A1 (en) | A method of local anesthesia and analgesia | |
JP2006516571A5 (ja) | ||
KR20180100309A (ko) | 데옥시콜산 및 이의 염을 사용한 축적된 지방의 치료 방법 | |
JP2001510795A5 (ja) | ||
JPH0647545B2 (ja) | 医薬用組成物 | |
JP4903694B2 (ja) | 抗血管形成作用を有する医薬の製造のためのトリフルオロ酢酸カルシウムの使用 | |
BR0315316A (pt) | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit | |
WO2001062799A3 (en) | Method for inhibiting angiogenesis using molecules that enhance plasmin activity | |
TWI310312B (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of macular degeneration | |
KR101451816B1 (ko) | 당뇨병성 창상의 예방 또는 치료용 약학 조성물 | |
TWI242447B (en) | An injectable pharmaceutical compositions of dalfopristine/quinupristine combination | |
JP2002530353A5 (ja) | ||
JPWO2008120562A1 (ja) | 帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法 | |
JPH0597697A (ja) | 歯槽骨再生剤 | |
KR20210126515A (ko) | 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물 | |
US20060165611A1 (en) | Composition for Treating and Preventing Periodontal Disease and Method of Use | |
WO2017019709A1 (en) | Composition and method for reducing scarring | |
JPH0692317B2 (ja) | 肛門用外用薬剤 | |
Magallon et al. | Low-level laser therapy as a coadjuvant in sodium hypochlorite extrusion management | |
Zhao et al. | Histological investigation of veins and venous malformations after injection of sclerosing agents | |
RU2326658C1 (ru) | Способ ведения послеоперационной раны на пародонте | |
Chen et al. | Intralesional pingyangmycin injection sclerotherapy for oral ranulas | |
JP3022915B2 (ja) | 癌転移抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080514 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111220 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120105 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150113 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |